| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.glandpharma.com | |
| Market Cap | 20,714.42 Cr. | |
| Enterprise Value(EV) | 17,421.88 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 60.00 | Trailing Twelve Months Ending 2022-12 |
| Price-Earning Ratio (PE) | 20.96 | Trailing Twelve Months Ending 2022-12 |
| Industry PE | 32.17 | Trailing Twelve Months Ending 2022-12 |
| Book Value / Share | 476.43 | Trailing Twelve Months Ending 2022-12 |
| Price to Book Value | 2.64 | Calculated using Price: 1,257.70 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 16.47 Cr. | 164,700,823 Shares |
| FaceValue | 1 | |
| Company Profile | ||
| The company was incorporated as Gland Pharma Private Limited, a private limited company, at Hyderabad under the Companies Act, 1956 on March 20, 1978 and was granted the certificate of incorporation by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, the name of the company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5, 1994, and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act, 1956. | ||
| 1 Day |
|
-0.01% |
| 1 Week |
|
+1.02% |
| 1 Month |
|
-4.51% |
| 3 Month |
|
-20.49% |
| 6 Month |
|
-39.82% |
| 1 Year |
|
-61.62% |
| 2 Year |
|
-47.82% |
| 5 Year |
|
|
| 10 Year |
|
| 3 years | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 21.29 | 20.97 | 18.61 | |
| Return on Capital Employed (%) | 27.39 | 28.00 | 24.85 | |
| Return on Assets (%) | 18.91 | 18.84 | 16.91 |
| Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 3,646 | 5,903 | 7,158 | 7,651 | |
| Non Curr. Liab. | 81 | 80 | 94 | 100 | |
| Curr. Liab. | 359 | 513 | 582 | 870 | |
| Minority Int. | |||||
| Equity & Liab. | 4,086 | 6,496 | 7,834 | 8,621 | |
| Non Curr. Assets | 1,240 | 1,372 | 1,982 | 2,312 | |
| Curr. Assets | 2,846 | 5,124 | 5,852 | 6,309 | |
| Misc. Exp. not W/O | |||||
| Total Assets | 4,086 | 6,496 | 7,834 | 8,621 |
| Particulars | 4 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
| Net Sales | 2,633 | 3,463 | 4,401 | 3,943 | |
| Other Income | 139 | 135 | 224 | 267 | |
| Total Income | 2,772 | 3,598 | 4,625 | 4,209 | |
| Total Expenditure | -1,678 | -2,161 | -2,891 | -2,738 | |
| PBIDT | 1,095 | 1,437 | 1,734 | 1,471 | |
| Interest | -7 | -3 | -5 | -7 | |
| Depreciation | -95 | -99 | -110 | -140 | |
| Taxation | -220 | -338 | -407 | -336 | |
| Exceptional Items | |||||
| PAT | 773 | 997 | 1,212 | 988 | |
| Minority Interest | |||||
| Share Associate | |||||
| Other Related Items | |||||
| Consolidated Net Profit | 773 | 997 | 1,212 | 988 | |
| Adjusted EPS | 50 | 61 | 74 | 60 |
| Particulars | 3 years | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 701 | 605 | 791 | |
| Cash Fr. Inv. | -766 | -1,524 | -1,003 | |
| Cash Fr. Finan. | -7 | 1,238 | 35 | |
| Net Change | -72 | 319 | -177 | |
| Cash & Cash Eqvt | 170 | 492 | 319 |
|
Wed, 29 Mar 2023
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s Recommendation for Appointment of Statutory Auditors of the Company |
|
Wed, 29 Mar 2023
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Allotment of 10 600 Equity shares under ESOP |
|
Fri, 24 Mar 2023
Closure of Trading Window Closure of Trading Window |
| Wed, 29 Mar 2023 |
Close Within 52 Week Low Zone
|
High Decrease in 3 Months
|
High Decrease in 6 Months
|
High Decrease in 1 Year
|
MFI Trending Up
|
Equities
M.F.
Sectors